Saudi ArabiaTuberculosis profile
Population  2016 32 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.84 (0.64–1.1) 2.6 (2–3.3)
Mortality (HIV+TB only) 0.013 (<0.01–0.017) 0.04 (0.03–0.05)
Incidence  (includes HIV+TB) 3.3 (2.9–3.9) 10 (8.9–12)
Incidence (HIV+TB only) 0.079 (0.066–0.094) 0.25 (0.2–0.29)
Incidence (MDR/RR-TB)** 0.13 (0.11–0.16) 0.41 (0.33–0.48)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.16 (0.14–0.19) 0.97 (0.82–1.1) 1.1 (0.96–1.3)
Males 0.18 (0.16–0.21) 2 (1.7–2.3) 2.2 (1.9–2.6)
Total 0.34 (0.29–0.4) 3 (2.6–3.5) 3.3 (2.9–3.9)
TB case notifications, 2016  
Total cases notified 3 004
Total new and relapse 2 913
          - % tested with rapid diagnostics at time of diagnosis 25%
          - % with known HIV status 65%
          - % pulmonary 74%
          - % bacteriologically confirmed among pulmonary 84%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.26 (0.19–0.34)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 45 2%
          - on antiretroviral therapy 43 96%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  94
(76–110)
Estimated % of TB cases with MDR/RR-TB 2.6% (2–3.2) 20% (14–26)  
% notified tested for rifampicin resistance 49% 60% 1 507
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 46, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 34, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 72% 3 309
Previously treated cases, excluding relapse, registered in 2015 44% 120
HIV-positive TB cases registered in 2015 45% 69
MDR/RR-TB cases started on second-line treatment in 2014 27% 55
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 3%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-17 Data: www.who.int/tb/data